Navigation Links
WuXi PharmaTech Provides Update of 2013 Financial Guidance, to Present at J.P. Morgan Healthcare Conference
Date:1/10/2014

SHANGHAI, Jan. 10, 2014 /PRNewswire/ -- WuXi PharmaTech (NYSE: WX), a leading pharmaceutical, biotechnology, and medical-device research and development services company, with operations in China and the United States, today announced that it updated its 2013 financial guidance. The company expects to achieve total revenues for full-year 2013 of approximately $578 million. The company expects diluted EPS for full-year 2013 to slightly exceed the top end of its previous guidance of $1.51-$1.55 (GAAP) and $1.73-$1.77 (non-GAAP). These preliminary 2013 results are unaudited and remain subject to the finalization of the company's year-end closing, reporting, and audit processes. The company plans to report its fourth-quarter and full-year 2013 financial results and to provide 2014 financial guidance in March 2014.

The company also announced that it will present at the 32th annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2014 at 8:30 a.m. Pacific Standard Time. The company's slides from the conference will be available on the company's Investor Relations page at www.wuxiapptec.com.

For more information, please contact:

Ronald Aldridge (for investors)
Director, Investor Relations
Tel: +1-201-585-2048
Email: ir@wuxiapptec.com

Aaron Shi (for the media)
Assistant Director, Corporate Communications
Tel: +86-21-5046-4362
Email: pr@wuxiapptec.com

Forward-Looking Statements

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not historical facts, but instead are predictions about future events. Examples of forward-looking statements in this press release include statements about the anticipated results for 2013, which remain subject to the finalization of the company's year-end closing, reporting, and audit processes. Although the company believes that its predictions are reasonable, future events are inherently uncertain, and its forward-looking statements may turn out to be incorrect. The company's forward-looking statements are subject to risks relating to, among other things, its ability to cost-effectively manage its chemistry service offerings, to meet goals for the expansion of its biologics service offerings, to protect its clients' intellectual property, and to compete effectively. Additional information about these and other relevant risks can be found in the company's Annual Report on Form 20-F for the year ended December 31, 2012. The forward-looking statements in this press release speak only as of the date on which they are made, and the company assumes no obligation to update any forward-looking statements except as required by law.

Use of Non-GAAP Financial Measures

The non-GAAP financial measures used in this press release are useful for understanding and assessing underlying business performance and operating trends, and the company believes that management and investors benefit from referring to these non-GAAP financial measures in assessing the company's financial performance and liquidity and when planning and forecasting future periods. You should not view non-GAAP results on a stand-alone basis or as a substitute for results under GAAP, or as being comparable to results reported or forecasted by other companies. Because the company's financial performance is subject to finalization of its year-end closing, reporting, and audit processes, the company does not provide a specific non-GAAP to US GAAP reconciliation. A reconciliation will be provided with the company's earnings release covering its fourth-quarter and full-year 2013 results. The non-GAAP guidance presented above is consistent with the presentation of non-GAAP results as reported in the company's March 7, 2013 press release covering its fourth-quarter and full-year 2012 results.


'/>"/>
SOURCE WuXi PharmaTech
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Winners of WuXi PharmaTech Awards Inducted into Prestigious Academies
2. WuXi PharmaTech Presents 2013 Life Science and Chemistry Awards
3. WuXi PharmaTech to Partner with Pharmacyclics
4. WuXi PharmaTech Announces Third-Quarter 2013 Results
5. WuXi PharmaTech Announces Licensing Agreement for Patient-Derived Xenograft Models with Mayo Clinics Center for Individualized Medicine
6. Zacks.com featured expert Kevin Matras highlights: Core Laboratories NV, Invesco Ltd., Medtronic, Inc., Willbros Group Inc. and WuXi PharmaTech Inc.
7. WuXi PharmaTech Schedules First-Quarter 2013 Earnings Release
8. Breckenridge announces agreement with Aptalis Pharmatech to market Propranolol Hydrochloride Extended-Release Capsules
9. WuXi PharmaTech Receives Letter from AAALAC Commending Animal Care at Suzhou Toxicology Facility as "Exemplary"
10. WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2012 Results, Share Repurchase Program
11. WuXi PharmaTech and Open Monoclonal Technology Expand Human Antibody Development and Commercial Opportunities for Asian Regional and Global Pharmaceutical Companies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... June 23, 2016 Research and ... Excipients Market by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), ... Topical, Coating, Parenteral) - Global Forecast to 2021" ... The global pharmaceutical excipients market is projected ... CAGR of 6.1% in the forecast period 2016 to ...
(Date:6/23/2016)... Roche (SIX: RO, ROG; OTCQX: RHHBY) announced ... BRAHMS PCT (procalcitonin) assay as a dedicated testing solution ... this clearance, Roche is the first IVD company in ... sepsis risk assessment and management. PCT is ... levels in blood can aid clinicians in assessing the ...
(Date:6/23/2016)... LOS ANGELES , June 23, 2016 /PRNewswire/ ... (NASDAQ: CAPR ), a biotechnology company ... first-in-class therapeutics, today announced that patient enrollment in ... progrEssion in Duchenne) has exceeded 50% of its ... its enrollment in the third quarter of 2016, ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... ... Brent Kasmer, a legally blind and certified personal trainer is helping to develop a weight ... app plans to fix the two major problems leading the fitness industry today:, ... program , They don’t eliminate all the reasons people quit their exercise program ...
(Date:6/25/2016)... Washington, D.C. (PRWEB) , ... June 25, 2016 ... ... will discuss health policy issues and applications at AcademyHealth’s Annual Research Meeting June ... share their work on several important health care topics including advance care planning, ...
(Date:6/25/2016)... ... June 25, 2016 , ... The temporary closing of Bruton Memorial Library on June 21 due ... up a new, often overlooked aspect of head lice: the parasite’s ability to live away ... a common occurrence, but a necessary one in the event that lice have simply gotten ...
(Date:6/25/2016)... ... ... First Choice Emergency Room , the largest network of independent freestanding emergency ... its new Mesquite-Samuell Farm facility. , “We are pleased to announce Dr. Ogunleye ... M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. , Dr. Ogunleye ...
(Date:6/25/2016)... Oklahoma City, Oklahoma (PRWEB) , ... June 25, ... ... to helping both athletes and non-athletes recover from injury. Recently, he has implemented ... for the Oklahoma City area —Johnson is one of the first doctors to ...
Breaking Medicine News(10 mins):